HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. - Wikidata - awgldk - TriplyDB

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

http://www.wikidata.org/entity/Q37157198

about

How to select the best available related or unrelated donor of hematopoietic stem cells?Natural Killer Cells for Therapy of Leukemia Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment Cord Blood as a Source of Natural Killer Cells Selection and expansion of natural killer cells for NK cell-based immunotherapy Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies Immune Modulation in Hematologic Malignancies NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Natural killer cell biology: an update and future directions Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies Killer immunoglobulin-like receptors and tumor immunity Manufacturing Natural Killer Cells as Medicinal Products Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Improving natural killer cell cancer immunotherapy Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans Design and Implementation of the International Genetics and Translational Research in Transplantation Network Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Maternal KIR in combination with paternal HLA-C2 regulate human birth weight.Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Phenotypic and functional activation of hyporesponsive KIRnegNKG2Aneg human NK-cell precursors requires IL12p70 provided by Poly(I:C)-matured monocyte-derived dendritic cells.Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease KIR diversity in Māori and Polynesians: populations in which HLA-B is not a significant KIR ligand.Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.Progress toward curing HIV infections with hematopoietic stem cell transplantation.Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation Blood and marrow transplant clinical trials network state of the Science Symposium 2014 Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Present and Future of Allogeneic Natural Killer Cell Therapy HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.Stress-Induced In Vivo Recruitment of Human Cytotoxic Natural Killer Cells Favors Subsets with Distinct Receptor Profiles and Associates with Increased Epinephrine Levels.

P2860

Q26744109-603E4758-57A8-4810-A5D8-9AEBD1BC6735 Q26745906-D20035FF-A415-483E-8C87-5E09C939E7CA Q26751011-24E06259-8B54-421C-B209-1DC225651D38 Q26765845-81E8C6E7-FF0B-4484-B1A9-7168F0371260 Q26771337-DA26E0A0-4628-471C-B5FD-8036BB0F4641 Q26774777-BF005897-9C78-4F35-9305-8DFC85956CA1 Q26776538-ED5B57AE-CFA9-4770-85B6-1F6AFC7845D4 Q26796307-BD613023-567E-4A77-9BB4-803D3746E629 Q26797345-4C4C6384-084B-48D4-BDB2-BA5EF04B5AA0 Q26830512-11523EB3-6C73-4651-BAC0-B420C078F592 Q26996660-5CF03E97-86D4-4CF0-8EF7-5B03583947C9 Q27005792-3E04E521-D149-4FBC-80C5-453B88D556CF Q28069992-44E17BD2-3304-42C0-99BD-0D8629EA1624 Q28080914-CBADDD75-E7FC-4C68-9534-D693C26DE01F Q28087719-A4AD8662-8FBE-4667-855D-14DDDFEA6DEE Q28534758-3369461B-704F-4381-9B64-C7FA455D8DE7 Q30366188-76567F53-4275-4F47-9C91-AE9869D3F749 Q30399209-A9DA65D0-4579-4F7D-8559-C7DDBB035327 Q33638193-333A7434-A655-46CF-8977-9C78BE4110B8 Q33642419-1C6A43A9-5984-4C5D-B234-A633001A8D0C Q33645271-C2682864-0EB1-481A-82B8-3B8ABC1337D6 Q33651178-318BAD07-A7DA-4E57-AC12-E60047AC665E Q33703046-00F43E0C-BD76-41EA-8CCF-5D5E3F607AFC Q33740971-430B6DE4-7C57-4C6C-B11E-CFBC56C95E2A Q34156998-152259C6-3475-43B5-BBC6-47979E147F16 Q34175568-9BAD2A00-5C26-4E78-B3A9-63EDC442DC68 Q34180695-C24294AE-1FE1-4C37-889A-2F19EAB92BFB Q34260505-8941B912-3371-4E9A-BAA7-3266D23F4BD9 Q34289351-A5E448BC-D111-4FCB-BBD9-764DDFCA30C1 Q34307792-9DED0156-89D4-4E54-A8F4-72451DF59128 Q34345310-E6A2A141-86AB-4AB7-8049-2A0618196207 Q34533074-EDD774FD-6750-4CD6-BB9B-053B9851D72F Q34688644-9293DCFC-40A0-418B-852E-B9372E5C7F0D Q34974480-347032E7-2785-4445-AF85-8530A287075B Q35242680-D34325B5-1FFF-4875-9E60-379830149512 Q35591760-81C13A75-963B-4536-A5C8-95508CDC2B59 Q35600095-1670C836-F8A7-4F57-8C70-E50111270E39 Q35677351-F898DEFC-DDE4-45B4-B376-06093B308DA9 Q35678422-8CD059DC-7C8C-4B73-B9F3-73AFDBB3CCE3 Q35877529-9EF2AFDB-F6C0-4A51-9DA7-A126825BF0CC

P2860

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

http://www.wikidata.org/entity/Q37157198

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@en

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@nl

type

label

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@en

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@nl

prefLabel

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@en

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@nl

P1433

Q37157198-BD0812ED-6A53-493A-B90C-FAB72554355B

P1476

Q37157198-59871D35-E271-4750-A72D-9BCADF79B322

P2093

Q37157198-0A878EB6-0EA0-4EB3-BF48-4C97C91EF3A5

Q37157198-380EE0ED-1860-4EC7-8735-619FC6C50200

Q37157198-5A4DF436-AACE-426E-87AF-FE1B1E2D2FC1

Q37157198-77C966D3-AF7E-42D5-9887-48705F6F8B72

Q37157198-8E6DACE7-6A5B-4656-9929-C6E10823EB6E

Q37157198-CB13E362-A1C3-484E-AA24-8CA1F062185D

Q37157198-CE6188FC-A2C6-4B26-89B7-831934A7BB40

Q37157198-DF083771-3EAE-4C47-8884-FAF571578B40

Q37157198-E5BAE5B9-6E13-49A6-90E3-FA7BFB592431

Q37157198-F446724D-913D-44B3-8D4F-3910763E417B

P2860

Q37157198-02C2BB86-D516-4C78-A7EA-0B448069FF69

Q37157198-07921314-68B8-4C94-ADA9-0E6F2EC45796

Q37157198-1526D89E-F205-40E6-AB3D-5828E8530049

Q37157198-1FF3C301-0E19-4B2B-AF37-03D5B4B468A0

Q37157198-3DD8EBFE-A89A-490D-9B38-1CA559B27DEE

Q37157198-433A2850-0D19-4094-B70C-C1BEF1B5084F

Q37157198-4907AD7A-5636-4C9B-85B4-0B279F2765B1

Q37157198-4959E4F6-164B-465A-8BE2-9F9CE5232C94

Q37157198-4E3554D6-C1E0-4BE0-B832-51786C30DE76

Q37157198-741C4F5E-418B-4B98-B9F5-F17FEC20588C

P304

Q37157198-BFD3C5FF-17FA-4EFE-A6B0-24B40AD0A145

P31

Q37157198-CDBE8134-9D17-4670-B4B8-B8DE5E4A566D

P356

Q37157198-845D122F-4F37-4722-BE59-36905EB5CC8E

P407

Q37157198-C9732986-FC58-4224-9AE8-3D2A1EC604A4

P433

Q37157198-091D0E9E-F737-4797-B881-B0D41D7A4D5A

P478

Q37157198-25052DA3-AD64-44AB-B9AC-BE2F062A7E1E

P577

Q37157198-DC19C4B0-EFA0-4431-AED9-C22D51EB55B1

P698

Q37157198-1F6EDDD4-4EC7-4A04-A088-1A07C5EDB88D

P921

Q37157198-7BC18FBC-7589-4EF4-B3C2-343F96BE6C28

P932

Q37157198-CF1D9DDE-22B4-4F36-B4A1-99390AD03E06

P356

P1433

The New England Journal of Medicine

P1476

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

@en

P2093

Bo Dupont

http://www.w3.org/2001/XMLSchema#string

Effie Petersdorf

http://www.w3.org/2001/XMLSchema#string

Gianfranco Pittari

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Venstrom

http://www.w3.org/2001/XMLSchema#string

Joseph H Chewning

http://www.w3.org/2001/XMLSchema#string

Katharine C Hsu

http://www.w3.org/2001/XMLSchema#string

Mari Malkki

http://www.w3.org/2001/XMLSchema#string

Meighan M Gallagher

http://www.w3.org/2001/XMLSchema#string

Michael Haagenson

http://www.w3.org/2001/XMLSchema#string

Stephen Spellman

http://www.w3.org/2001/XMLSchema#string

P2860

NK cell recognition

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation

Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors

Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.

Human natural killer cell receptors and co-receptors.

P304

805-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1200503

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22931314

http://www.w3.org/2001/XMLSchema#string

P921

P932

3767478

http://www.w3.org/2001/XMLSchema#string